Editorial: Do non-antiarrhythmic drugs have enough pleiotropic power to reduce atrial fibrillation?

Europace

Volumn 12, Issue 3, 2010, Pages 299-300

  Folkeringa, Richard J ^a   Crijns, Harry J G M ^a  

^a CATHARINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CARDIOVASCULAR AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM ANTAGONIST; UNCLASSIFIED DRUG; ANTIARRHYTHMIC AGENT;

EDITORIAL; GENDER; HEART AFTERLOAD; HEART ATRIUM FIBRILLATION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; HIGH RISK POPULATION; HUMAN; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENCE RISK; NOTE; PATHOPHYSIOLOGY; RISK FACTOR;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; HUMANS; RISK FACTORS;

EID: 77749324861     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euq009     Document Type: Editorial

References (9)

1. Dagres N, Nieuwlaat N, Vardas PE, Andresen D, Lévy S, Cobbe S et al. Genderrelated differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe. A report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol 2007;49:572-7.
2. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/AHA/ESC 2006 guidelines for the managment of patients with atrial fibrillation: full text. A report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:651-745.
3. Patel D, Mohanty P, Di Biase L, Wang Y, Shaheen MH, Sanchez JE et al. The impact of statins and renin-angiotensin-aldosteron system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females. Europace 2010;12:322-30.
4. Healey JS, Baranchuk A, Chrystal E, Morillo CA, Garfinkle M, Yusuf S et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-9.
5. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101: 2612-7.
6. Engelmann MDM, Svedsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005;26:2083-92.
7. Adam O, Neuberger HR, Böhm M, Laufs U. Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Circulation 2008;118:1285-93.
8. Shah DP. Electrophysiological evaluation of pulmonary vein isolation. Europace 2009;11:1423-33.
9. De Ponti R, Verlato R, Bertaglia E, Del Greco M, Fusco A, Bottoni N et al. Treatment of macro-re-entrant atrial tachycardia based on electroanatomic mapping: identification and ablation of the mid-diastolic isthmus. Europace 2007;9:449-57.